Gan & Lee Pharmaceuticals vs Baxter International: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Gan & Lee Pharmaceuticals Co Ltd (603087.CG)

Q3 202627 Jul – 8 Oct 2026

▲4

Gan & Lee's obesity drug goes global as pipeline and profits advance

Menarini deal takes obesity drug to Europe Gan & Lee licensed its biweekly obesity drug bofanglutide to Menarini for 39 European countries. It gets 62 million euros upfront, up to 664 million euros in milestones, and royalties — total potential value 726 million euros. This is its fourth and largest overseas deal, proving the drug's global value and boosting future revenue.
This is the biggest new event, directly adding cash and validating the company's key pipeline.
Oral weekly diabetes drug moves to human trials Gan & Lee's GZC8072 tablets won Chinese clinical trial approval for type 2 diabetes. It is an oral peptide taken once a week, a next-generation product from its own technology platforms. This opens a large, convenient oral market and strengthens its long-term pipeline beyond injectables.
New regulatory milestone for a key pipeline asset, showing future growth potential.
Ethiopian approval opens new insulin market Ethiopia approved Gan & Lee's insulin aspart injection Rapilin for diabetes. Ethiopia has about 2.3 million diabetes patients and no other insulin aspart products, so this is a first-mover opportunity. It follows EU and Bolivia approvals, expanding the company's international reach.
New market approval that adds to the company's growing international revenue stream.
First-half profit and cash flow stay solid Gan & Lee reported first-half 2026 revenue of 2.223 billion yuan and net profit of 610 million yuan, with strong cash inflow and a very low debt ratio. International revenue jumped 92% year on year, showing its overseas push is paying off and supporting the stock's valuation.
Confirms the company's financial health and growth, underpinning investor confidence.

September 202627 Jul – 8 Oct 2026

▲4

Gan & Lee's obesity drug goes global as pipeline and profits advance

Menarini deal takes obesity drug to Europe Gan & Lee licensed its biweekly obesity drug bofanglutide to Menarini for 39 European countries. It gets 62 million euros upfront, up to 664 million euros in milestones, and royalties — total potential value 726 million euros. This is its fourth and largest overseas deal, proving the drug's global value and boosting future revenue.
This is the biggest new event, directly adding cash and validating the company's key pipeline.
Oral weekly diabetes drug moves to human trials Gan & Lee's GZC8072 tablets won Chinese clinical trial approval for type 2 diabetes. It is an oral peptide taken once a week, a next-generation product from its own technology platforms. This opens a large, convenient oral market and strengthens its long-term pipeline beyond injectables.
New regulatory milestone for a key pipeline asset, showing future growth potential.
Ethiopian approval opens new insulin market Ethiopia approved Gan & Lee's insulin aspart injection Rapilin for diabetes. Ethiopia has about 2.3 million diabetes patients and no other insulin aspart products, so this is a first-mover opportunity. It follows EU and Bolivia approvals, expanding the company's international reach.
New market approval that adds to the company's growing international revenue stream.
First-half profit and cash flow stay solid Gan & Lee reported first-half 2026 revenue of 2.223 billion yuan and net profit of 610 million yuan, with strong cash inflow and a very low debt ratio. International revenue jumped 92% year on year, showing its overseas push is paying off and supporting the stock's valuation.
Confirms the company's financial health and growth, underpinning investor confidence.

Latest27 Jul – 8 Oct 2026

▲4

Gan & Lee's obesity drug goes global as pipeline and profits advance

Menarini deal takes obesity drug to Europe Gan & Lee licensed its biweekly obesity drug bofanglutide to Menarini for 39 European countries. It gets 62 million euros upfront, up to 664 million euros in milestones, and royalties — total potential value 726 million euros. This is its fourth and largest overseas deal, proving the drug's global value and boosting future revenue.
This is the biggest new event, directly adding cash and validating the company's key pipeline.
Oral weekly diabetes drug moves to human trials Gan & Lee's GZC8072 tablets won Chinese clinical trial approval for type 2 diabetes. It is an oral peptide taken once a week, a next-generation product from its own technology platforms. This opens a large, convenient oral market and strengthens its long-term pipeline beyond injectables.
New regulatory milestone for a key pipeline asset, showing future growth potential.
Ethiopian approval opens new insulin market Ethiopia approved Gan & Lee's insulin aspart injection Rapilin for diabetes. Ethiopia has about 2.3 million diabetes patients and no other insulin aspart products, so this is a first-mover opportunity. It follows EU and Bolivia approvals, expanding the company's international reach.
New market approval that adds to the company's growing international revenue stream.
First-half profit and cash flow stay solid Gan & Lee reported first-half 2026 revenue of 2.223 billion yuan and net profit of 610 million yuan, with strong cash inflow and a very low debt ratio. International revenue jumped 92% year on year, showing its overseas push is paying off and supporting the stock's valuation.
Confirms the company's financial health and growth, underpinning investor confidence.

Baxter International Inc (BAX)

Q3 202629 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.

August 202629 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.

Latest29 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.